Treatment
Ravulizumab clinical trials
We’re tracking 12 recruiting studies that include Ravulizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT07399730Recruiting
Study of ravulizumab outcomes in Polish aHUS patients
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
GdanskAges 18 years+ - NCT06830798RecruitingPhase 3
Ravulizumab to prevent delayed graft function after kidney transplant
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
Phoenix, ArizonaAges 18 years+ - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT06333652RecruitingPhase 2
Ravulizumab for severe pregnancy hypertension disorders
This study tests a medicine called Ravulizumab for pregnant people with severe high blood pressure problems (preeclampsia or HELLP syndrome) before 34 weeks of pregnancy. The goal is to see if the drug can help manage the condition and improve outcomes for both mother and baby.
Rochester, MinnesotaAges 18–50 - NCT06398158Recruiting
Ravulizumab and its impact on neuromyelitis optica
This study looks at how well ravulizumab (Ultomiris) works for people with neuromyelitis optica spectrum disorder (NMOSD) by tracking symptoms and MRI scans over time. It aims to see if the drug helps control the disease in real-world use.
Dallas, TexasAges 18 years+ - NCT06909253Recruiting
Study of ravulizumab for generalized myasthenia gravis
This study looks at how well ravulizumab works for people with generalized myasthenia gravis (gMG) who have not tried complement inhibitors before. The goal is to see if this treatment helps improve symptoms in everyday life.
BydgoszczAges 18 years+ - NCT06967480Recruiting
Early ravulizumab for recent-onset generalized myasthenia gravis
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
BergamoAges 18 years+ - NCT07221838RecruitingPhase 4
Steroid Tapering Study for Myasthenia Gravis on Ravulizumab
This study is for people with generalized myasthenia gravis who are already on ravulizumab and a daily steroid. It aims to see if the steroid dose can be safely lowered over time.
Chicago, IllinoisAges 18 years+ - NCT07308574RecruitingPhase 4
Ravulizumab for aHUS patients
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
Bunkyō CityAges 18 years+ - NCT07411963Recruiting
Early ravulizumab for severe myasthenia gravis crisis in the ICU
This study tests whether starting ravulizumab early, after plasma exchange or IVIg, can help people with a severe myasthenia gravis crisis who are in the intensive care unit. It aims to see if it improves their condition.
Nice, Alpes-maritimesAges 18 years+ - NCT06312644Recruiting
Study of Ultomiris safety during pregnancy
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Boston, MassachusettsAges Any age - NCT06449001RecruitingPhase 3
Danicopan plus standard therapy for pediatric PNH
This trial tests adding danicopan to a standard treatment (ravulizumab or eculizumab) for children with PNH who still have anemia from extravascular hemolysis. The goal is to see if the combination helps improve red blood cell counts.
Saskatoon, SaskatchewanAges 12–17
What Ravulizumab is being studied for
Conditions with recruiting Ravulizumab studies.
Common questions
- Are there clinical trials studying Ravulizumab?
- Yes. Clin2 currently lists 12 recruiting studies that include Ravulizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ravulizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ravulizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ravulizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.